| abstract |
A method for treating asthma in a patient using an agent selected from the group consisting of: (a) an antibody capable of binding to ELAM-1; (b) a fragment of the antibody (a), the fragment being capable of binding to ELAM-1; (c) ELAM-1, being substantially free of natural contaminants; (d) a functional derivative of ELAM-1; (e) an antibody capable of binding to an ELAM-1 receptor; (f) a fragment of the antibody (e), the fragment being capable of binding to an ELAM-1 receptor; (g) an ELAM-1 receptor, being substantially free of natural contaminants; and (h) a functional derivative of an ELAM-1 receptor. |